Interaction Checker

Wechselwirkungen von Bendamustin

Bendamustin (Treanda, Bendeka, Belrapzo) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 91 dokumentierte Wechselwirkungen: 2 schwerwiegende, 89 mittelschwere, 0 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (2)

  • AllopurinolXanthinoxidasehemmerSchwerwiegend

    However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly. [see Warnings and Precautions (5.6) ] 5.6 Skin Reactions Fatal and serious skin reactions have been reported with bendamustine hydrochloride injection treatment in clinical trials and postmarketing safety reports, including… (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • RituximabImmunsuppressivumSchwerwiegend

    Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions (6.2) ] . (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

Mittelschwere Wechselwirkungen (89)

  • AbataceptImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • AbrocitinibJAK-InhibitorMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • AdalimumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • AlemtuzumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • AzathioprinImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • AzelastinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Azelastin und FluticasonAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • BaricitinibJAK-InhibitorMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Brompheniramin, Pseudoephedrin und DextromethorphanAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • BudesonidKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Cannabidiol (verschreibungspflichtig)AntiepileptikumMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • CarbamazepinAntiepileptikumMittelschwer

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • CarbinoxaminAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • CetirizinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • ChlorphenaminAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclosporinImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • CimetidinH2-BlockerMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • CiprofloxacinFluorchinolonMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • CladribinAntimetabolitMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • ClemastinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • CyclophosphamidImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • CyproheptadinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DeferasiroxEisenpräparatMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • DeflazacortKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DesloratadinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DesonidKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DexchlorpheniraminAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DimenhydrinatAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DimethylfumaratImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DiphenhydraminAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • DoxylaminAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Doxylamin und PyridoxinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • EtanerceptImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • EverolimusImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FexofenadinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FingolimodImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FludrocortisonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • FluvoxaminSSRIMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • GuselkumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • HalobetasolKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Hydrocodon und ChlorphenaminOpioidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • HydroxyzinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • InfliximabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • LeflunomidImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • LevocetirizinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • LoratadinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • MeclozinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • MercaptopurinAntimetabolitMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • MethotrexatImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylprednisolonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • MexiletinAntiarrhythmikumMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • MometasonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • MycophenolatImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • NatalizumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • OcrelizumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • OlopatadinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • PimecrolimusCalcineurin-InhibitorMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • PonesimodImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • PromethazinAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und CodeinOpioidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Promethazin und DextromethorphanAntihistaminikumMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • RitlecitinibJAK-InhibitorMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • SecukinumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • SirolimusImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • TacrolimusImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • TeriflunomidImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • TocilizumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • TofacitinibImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • TriamcinolonKortikosteroidMittelschwer

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • UpadacitinibImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • UstekinumabImmunsuppressivumMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • ViloxazinNoradrenalin-WiederaufnahmehemmerMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

  • ZileutonCYP1A2-HemmerMittelschwer

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Bendamustin, Arzneimittelwechselwirkungen)

Prüfen Sie Bendamustin gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.